

Yasuhiro Tsutani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1838114/publications.pdf>

Version: 2024-02-01

140
papers

2,737
citations

236833

25
h-index

214721

47
g-index

141
all docs

141
docs citations

141
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1317-1324.	0.7	2
2	Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1608-1616.	0.7	25
3	Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1617-1623.	0.7	2
4	Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2022, 23, e9-e16.e1.	1.1	2
5	Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pNOMO EGFR-mutant lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1419-1428.	1.2	2
6	Segmentectomy versus lobectomy for solid predominant cNO lung cancer: analysis using visual evaluation of positron emission tomography. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 279-286.	0.6	5
7	Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	8
8	The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1306-1315.e4.	0.4	14
9	Techniques of Minimally Invasive Posterior Basal (S10) Segmentectomies of the Lower Lobes. <i>Operative Techniques in Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.2	1
10	Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 753-759.	0.5	5
11	Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, , .	0.5	1
12	The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	10
13	Reply to Zhou <i>et al.</i>. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	0
14	A Multicenter Study of Complex Segmentectomy versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	3
15	Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non-“small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1244-1252.e1.	0.4	27
16	Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces. <i>Annals of Thoracic Surgery</i> , 2021, 112, 935-943.	0.7	25
17	Prognostic impact of a ground-glass opacity component in clinical stage IA non-“small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1469-1480.	0.4	83
18	Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 281-290.	0.4	35

#	ARTICLE	IF	CITATIONS
19	Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 28-36.	0.6	8
20	Oncologic Outcomes of Complex Segmentectomy: A Multicenter Propensity Score-Matched Analysis. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1044-1051.	0.7	12
21	Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography. <i>Clinical Lung Cancer</i> , 2021, 22, e431-e437.	1.1	4
22	Surgical Procedure Selection for Stage I Lung Cancer: Complex Segmentectomy versus Wedge Resection. <i>Clinical Lung Cancer</i> , 2021, 22, e224-e233.	1.1	7
23	Patient Selection of Sublobar Resection Using Visual Evaluation of Positron-Emission Tomography (PET) for Early-Stage Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 2068-2075.	0.7	7
24	Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100126.	0.6	10
25	Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2021, 10, 766-775.	1.3	3
26	Bronchial mucosal ablation for bronchial stump closure in right pneumonectomy: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 71.	0.4	2
27	Impact of postoperative pleurodesis on pulmonary function after lung segmentectomy. <i>JTCVS Open</i> , 2021, 5, 110-118.	0.2	5
28	Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 120-126.e3.	1.1	7
29	Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL). <i>BMJ Open</i> , 2021, 11, e043234.	0.8	3
30	Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655651.	1.3	12
31	Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3709-3718.	1.2	8
32	Prognostic role of interstitial pneumonia with or without emphysema in patients with clinical stage I lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1123-1131.	0.6	1
33	Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 10105.	1.6	5
34	Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer. <i>BMC Pulmonary Medicine</i> , 2021, 21, 186.	0.8	7
35	Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 622742.	1.3	4
36	Postoperative Pulmonary Function After Complex Segmentectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8347-8355.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Prediction of Acute Exacerbation of Interstitial Pneumonia Using Visual Evaluation of PET. <i>Annals of Thoracic Surgery</i> , 2021, 112, 264-270.	0.7	5
38	ASO Author Reflection: Position of the Complex Segmentectomy on Postoperative Pulmonary Function. <i>Annals of Surgical Oncology</i> , 2021, 28, 8356-8357.	0.7	0
39	Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1561-1569.	0.6	5
40	Systematic Versus Lobe-Specific Mediastinal Lymphadenectomy for Hypermetabolic Lung Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7162-7171.	0.7	14
41	The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study. <i>Lung Cancer</i> , 2021, 158, 9-14.	0.9	12
42	ASO Author Reflections: Survival Outcomes between Patients with Hypermetabolic Non-small Cell Lung Cancer Undergoing Systematic and Lobe-Specific Mediastinal Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 7172-7172.	0.7	0
43	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 333-344.	0.6	6
44	Reply to "Lobe-Specific Lymph Node Dissection for Lung Cancer: Is It Still Feasible?" by Han-Yu Deng. <i>Annals of Surgical Oncology</i> , 2021, 28, 848-849.	0.7	5
45	Pathological high malignant grade is higher risk of recurrence in <i>scp</i> pNOMO <i>scp</i> invasive lung adenocarcinoma, even with small invasive size. <i>Thoracic Cancer</i> , 2021, 12, 3141-3149.	0.8	5
46	Reply to Zhang <i>et al.</i> . <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 928-928.	0.6	0
47	ASO Author Reflections: Usefulness of Visual Evaluation of PET in Predicting Prognosis after Lung Resection for Early-Stage Lung Adenocarcinoma and Selecting Candidates for Sublobar Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 2076-2077.	0.7	0
48	Appropriate Extent of Lymphadenectomy in Segmentectomy: A Multicenter Study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 451-458.	0.6	5
49	Segmentectomy for STAS positive lung adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	0
50	Reply to Li and Che. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 614-615.	0.6	0
51	Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 114-121.	0.6	56
52	Albumin/globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	1.0	25
53	Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 485-492.	1.2	17
54	Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pNOMO Lung Adenocarcinoma with the Micropapillary Component. <i>Annals of Surgical Oncology</i> , 2020, 27, 945-955.	0.7	11

#	ARTICLE	IF	CITATIONS
55	Investigation of surgical technique for bronchial stump closure after lobectomy in animal model. <i>General Thoracic and Cardiovascular Surgery</i> , 2020, 68, 609-614.	0.4	4
56	Predicting Severe Postoperative Complication in Patients With Lung Cancer and Interstitial Pneumonia. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1054-1060.	0.7	20
57	A multi-institutional randomized phase III trial comparing anatomical segmentectomy and wedge resection for clinical stage IA non-small cell lung cancer in high-risk operable patients: Japan Clinical Oncology Group Study JCOG1909 (ANSWER study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1209-1213.	0.6	8
58	Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1530-1536.	0.7	15
59	Prognosis of segmentectomy and lobectomy for radiologically aggressive small-sized lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1245-1253.	0.6	19
60	Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30mm. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1306-1312.	0.6	2
61	Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm. <i>Clinical Lung Cancer</i> , 2020, 21, e528-e538.	1.1	24
62	Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1076-1079.	0.6	19
63	Wedge resection as an alternative treatment for octogenarian and older patients with early-stage non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1051-1057.	0.6	12
64	Oncologic outcomes of lobectomy vs. segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2020, 12, 3178-3187.	0.6	10
65	Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. <i>Lung Cancer</i> , 2020, 141, 107-113.	0.9	33
66	Initial experience of robotic anatomical segmentectomy for non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 440-445.	0.6	5
67	Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e302-e314.	1.1	11
68	Diagnostic performance of peripheral leukocyte telomere G-tail length for detecting breast cancer. <i>Cancer Science</i> , 2020, 111, 1856-1861.	1.7	8
69	Prediction of Lymph Node Metastasis Using Semiquantitative Evaluation of PET for Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1036-1042.	0.7	16
70	Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles. <i>Cancer Science</i> , 2020, 111, 2104-2115.	1.7	32
71	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231116.	1.1	22
72	Prediction of lymph node metastasis using 5-point visual scale criteria of [18F]-fluoro-2-deoxy-D-glucose on positron emission tomography / computed tomography for early stage lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e21084-e21084.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Abstract 1402: Preclinical evaluation of a novel senescence-associated miRNA miR-3140-3p for malignant pleural mesothelioma. , 2020, , .		0
74	Abstract 5594: Immune gene expression by nCounter in mucinous adenocarcinoma lung cancer. , 2020, , .		0
75	Abstract P3-04-01: Telomere G-tail length correlates with the presence of breast cancer. , 2020, , .		0
76	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
77	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
78	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
79	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
80	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
81	Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. , 2020, 15, e0231116.		0
82	Metachronous Lung Cancer After Pleurectomy/Decortication. <i>Annals of Thoracic Surgery</i> , 2019, 107, e1-e3.	0.7	0
83	Guanylate binding protein 1 (GBP-1) promotes cell motility and invasiveness of lung adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 266-272.	1.0	15
84	Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2325-2333.	1.2	7
85	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 451-459.	0.9	76
86	High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1484-1490.	0.7	26
87	Postoperative Recurrence and Survival After Segmentectomy for Clinical Stage 0 or IA Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 397-403.e1.	1.1	17
88	Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma. <i>Oncology Letters</i> , 2019, 17, 3607-3614.	0.8	8
89	Surgical Outcomes of Complex Versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1032-1039.	0.7	72
90	Wedge resection versus segmentectomy in patients with stage I non-small-cell lung cancer unfit for lobectomy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1134-1142.	0.6	20

#	ARTICLE	IF	CITATIONS
91	Prospective feasibility study of sealing pulmonary vessels with energy in lung surgery. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 388-395.	0.4	9
92	Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. Histopathology, 2019, 74, 545-554.	1.6	13
93	Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study.. Journal of Clinical Oncology, 2019, 37, 8500-8500.	0.8	5
94	Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer.. Journal of Clinical Oncology, 2019, 37, 8525-8525.	0.8	0
95	Abstract 2577: Circulating micro RNA/isomiRs as novel biomarker of esophageal squamous cell carcinoma. , 2019, , .		0
96	Abstract 2853: Cell motility and invasiveness are promoted by guanylate binding protein 1, GBP-1 in lung adenocarcinoma. , 2019, , .		0
97	Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1aâ€bN0M0ÂLung Cancer. World Journal of Surgery, 2018, 42, 2493-2501.	0.8	26
98	Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors. Annals of Thoracic Surgery, 2018, 105, 1543-1550.	0.7	5
99	The differences in histological changes among pulmonary vessels divided with an energy device. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 372-378.	0.5	1
100	Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2018, 53, 366-371.	0.6	40
101	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer, 2018, 18, 1231.	1.1	10
102	Increased risk of recurrence in resected <i>EGFR</i>â€positive pNOMO invasive lung adenocarcinoma. Thoracic Cancer, 2018, 9, 1594-1602.	0.8	19
103	Bronchoplasties at the Segmental Level. Thoracic Surgery Clinics, 2018, 28, 299-304.	0.4	2
104	Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT.. Journal of Clinical Oncology, 2018, 36, 8554-8554.	0.8	0
105	Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers. General Thoracic and Cardiovascular Surgery, 2017, 65, 392-399.	0.4	3
106	Outcomes after lobar versus sublobar resection for clinical stage I nonâˆ³small cell lung cancer in patients with interstitial lung disease. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1089-1096.e1.	0.4	42
107	OA15.03 Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease. Journal of Thoracic Oncology, 2017, 12, S302.	0.5	1
108	P1.05-056 Increased Risk of Postoperative Recurrence in EGFR-Positive Stage IA to IB Invasive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, S649.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1896-1901.	0.7	17
110	Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1112-1118.	0.6	57
111	Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. <i>Oncotarget</i> , 2017, 8, 108936-108945.	0.8	9
112	Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 51, ezw318.	0.6	10
113	Preoperative predictors of distant recurrence in patients with clinical stage IA lung adenocarcinoma undergoing complete resection. <i>Japanese Journal of Clinical Oncology</i> , 2016, 47, 157-163.	0.6	0
114	Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1668-1673.	0.7	46
115	Complete transection of the left main bronchus caused by blunt thoracic trauma in a child treated by bronchoplasty and lung parenchyma preservation. <i>General Thoracic and Cardiovascular Surgery</i> , 2016, 64, 113-115.	0.4	2
116	Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, 433-440.e1.	1.1	1
117	What are the radiologic findings predictive of indolent lung adenocarcinoma?. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 367-372.	0.6	19
118	Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 1022-1026.	0.6	16
119	Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung. <i>General Thoracic and Cardiovascular Surgery</i> , 2015, 63, 153-158.	0.4	3
120	Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1 α and glucose transporter 1 in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 138.	0.6	7
121	Segmentectomy for clinical stage IA lung adenocarcinoma showing solid dominance on radiology. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 637-642.	0.6	40
122	Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1820-1826.	0.4	33
123	Sublobar Resection for Lung Adenocarcinoma Meeting Node-Negative Criteria on Preoperative Imaging. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1701-1707.	0.7	33
124	Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1179-1185.	0.4	33
125	Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma. <i>Chest</i> , 2014, 145, 66-71.	0.4	280
126	Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma. <i>Annals of Cardiothoracic Surgery</i> , 2014, 3, 153-9.	0.6	48

#	ARTICLE	IF	CITATIONS
127	Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: Prognostic comparison using high-resolution computed tomography findings. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 17-23.	0.4	105
128	Reply to the Editor. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1148-1149.	0.4	0
129	The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 580-585.	0.4	77
130	Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1958-1965.	0.7	66
131	Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: Propensity score-matched analysis in a multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 358-364.	0.4	176
132	Lung metastasis of adenoid cystic carcinoma, which mimicked primary lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 327-329.	0.8	4
133	Radical hybrid video-assisted thoracic segmentectomy: long-term results of minimally invasive anatomical sublobar resection for treating lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 14, 5-11.	0.5	50
134	Non-small-cell lung cancer prognosis using carcinoembryonic antigen levels in pleural lavage fluid. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, e96-e101.	0.6	7
135	Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 1365-1371.	0.4	117
136	Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 607-612.	0.4	195
137	Difference in Prognostic Significance of Maximum Standardized Uptake Value on [18F]-Fluoro-2-Deoxyglucose Positron Emission Tomography Between Adenocarcinoma and Squamous Cell Carcinoma of the Lung. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 890-896.	0.6	59
138	Dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in esophageal cancer patients: Correlation with clinicopathological factors and prognosis. <i>Molecular Medicine Reports</i> , 2008, 1, 713-9.	1.1	4
139	Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line. <i>Oncology Reports</i> , 2008, 20, 1545-51.	1.2	14
140	Appropriate treatment strategy for ground glass opacity-dominant non-small cell lung cancer. <i>Video-Assisted Thoracic Surgery</i> , 0, 3, 34-34.	0.1	1